Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

A novel salicylanilide derivative induces autophagy cell death in castration-resistant prostate cancer via ER stress-activated PERK signaling pathway.

Hsieh CL, Huang HS, Chen KC, Saka T, Chiang CY, Chung LWK, Sung SY.

Mol Cancer Ther. 2019 Sep 17. pii: molcanther.0387.2019. doi: 10.1158/1535-7163.MCT-19-0387. [Epub ahead of print]

PMID:
31530650
2.

Colorimetric Calcium Probe with Comparison to an Ion-Selective Optode.

Zhu C, Huang M, Lan J, Chung LW, Li X, Xie X.

ACS Omega. 2018 Oct 3;3(10):12476-12481. doi: 10.1021/acsomega.8b01813. eCollection 2018 Oct 31.

3.

A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM.

Theranostics. 2019 Apr 13;9(10):2812-2826. doi: 10.7150/thno.34485. eCollection 2019.

4.

Establishment and characterization of a prostate cancer cell line from a prostatectomy specimen for the study of cellular interaction.

Wang R, Chu GC, Wang X, Wu JB, Hu P, Multani AS, Pathak S, Zhau HE, Chung LWK.

Int J Cancer. 2019 Oct 15;145(8):2249-2259. doi: 10.1002/ijc.32370. Epub 2019 May 10.

PMID:
31020641
5.

Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.

Mrdenovic S, Zhang Y, Wang R, Yin L, Chu GC, Yin L, Lewis M, Heffer M, Zhau HE, Chung LWK.

Cancer. 2019 Mar 6. doi: 10.1002/cncr.32033. [Epub ahead of print]

6.

Enantioselective Rhodium-Catalyzed Cycloisomerization of 1,6-Allenynes to access 5/6-Fused Bicycle[4.3.0]nonadienes.

Deng X, Shi LY, Lan J, Guan YQ, Zhang X, Lv H, Chung LW, Zhang X.

Nat Commun. 2019 Feb 27;10(1):949. doi: 10.1038/s41467-019-08900-z.

7.

Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics.

Chu GC, Chung LWK, Gururajan M, Hsieh CL, Josson S, Nandana S, Sung SY, Wang R, Wu JB, Zhau HE.

Asian J Urol. 2019 Jan;6(1):65-81. doi: 10.1016/j.ajur.2018.11.003. Epub 2018 Nov 28. Review.

8.

Asymmetric Total Synthesis of Cerorubenic Acid-III.

Liu X, Liu J, Wu J, Huang G, Liang R, Chung LW, Li CC.

J Am Chem Soc. 2019 Feb 20;141(7):2872-2877. doi: 10.1021/jacs.8b12647. Epub 2019 Feb 7.

PMID:
30721058
9.

Novel Molecular Doping Mechanism for n-Doping of SnO2 via Triphenylphosphine Oxide and Its Effect on Perovskite Solar Cells.

Tu B, Shao Y, Chen W, Wu Y, Li X, He Y, Li J, Liu F, Zhang Z, Lin Y, Lan X, Xu L, Shi X, Ng AMC, Li H, Chung LW, Djurišić AB, He Z.

Adv Mater. 2019 Apr;31(15):e1805944. doi: 10.1002/adma.201805944. Epub 2019 Jan 30.

PMID:
30697836
10.

Kinetic Resolution of Alkylidene Norcamphors via a Ligand-Controlled Umpolung-Type 1,3-Dipolar Cycloaddition.

Shen C, Yang Y, Wei L, Dong WW, Chung LW, Wang CJ.

iScience. 2019 Jan 25;11:146-159. doi: 10.1016/j.isci.2018.12.010. Epub 2018 Dec 15.

11.

A Missing Piece of the Mechanism in Metal-Catalyzed Hydrogenation: Co(-I)/Co(0)/Co(+I) Catalytic Cycle for Co(-I)-Catalyzed Hydrogenation.

Wu SB, Zhang T, Chung LW, Wu YD.

Org Lett. 2019 Jan 18;21(2):360-364. doi: 10.1021/acs.orglett.8b03463. Epub 2019 Jan 2.

PMID:
30600680
12.

Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer.

Hsiao WC, Sung SY, Chung LWK, Hsieh CL.

Methods Mol Biol. 2019;1895:27-42. doi: 10.1007/978-1-4939-8922-5_3.

PMID:
30539527
13.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.

Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.

14.

Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential.

Reis-Sobreiro M, Chen JF, Novitskaya T, You S, Morley S, Steadman K, Gill NK, Eskaros A, Rotinen M, Chu CY, Chung LWK, Tanaka H, Yang W, Knudsen BS, Tseng HR, Rowat AC, Posadas EM, Zijlstra A, Di Vizio D, Freeman MR.

Cancer Res. 2018 Nov 1;78(21):6086-6097. doi: 10.1158/0008-5472.CAN-18-0608. Epub 2018 Aug 28.

PMID:
30154147
15.

R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.

Lin TP, Li J, Li Q, Li X, Liu C, Zeng N, Huang JM, Chu GC, Lin CH, Zhau HE, Chung LWK, Wu BJ, Shih JC.

Mol Cancer Res. 2018 Dec;16(12):1940-1951. doi: 10.1158/1541-7786.MCR-16-0346. Epub 2018 Jul 24.

PMID:
30042175
16.

Correction to Brønsted-Acid-Promoted Rh-Catalyzed Asymmetric Hydrogenation of N-Unprotected Indoles: A Cocatalysis of Transition Metal and Anion Binding.

Wen J, Fan X, Tan R, Chien HC, Zhou Q, Chung LW, Zhang X.

Org Lett. 2018 Jul 20;20(14):4390. doi: 10.1021/acs.orglett.8b01912. Epub 2018 Jul 9. No abstract available.

PMID:
29984575
17.

Silicon-oriented regio- and enantioselective rhodium-catalyzed hydroformylation.

You C, Li X, Yang Y, Yang YS, Tan X, Li S, Wei B, Lv H, Chung LW, Zhang X.

Nat Commun. 2018 May 23;9(1):2045. doi: 10.1038/s41467-018-04277-7.

18.

Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells.

Grindel BJ, Martinez JR, Tellman TV, Harrington DA, Zafar H, Nakhleh L, Chung LW, Farach-Carson MC.

Sci Rep. 2018 May 8;8(1):7262. doi: 10.1038/s41598-018-25435-3.

19.

Rhodium-catalyzed asymmetric hydrogenation of β-cyanocinnamic esters with the assistance of a single hydrogen bond in a precise position.

Li X, You C, Yang Y, Yang Y, Li P, Gu G, Chung LW, Lv H, Zhang X.

Chem Sci. 2018 Jan 4;9(7):1919-1924. doi: 10.1039/c7sc04639a. eCollection 2018 Feb 21.

20.

Catalytic asymmetric trifluoromethylthiolation of carbonyl compounds via a diastereo and enantioselective Cu-catalyzed tandem reaction.

Jin MY, Li J, Huang R, Zhou Y, Chung LW, Wang JJ.

Chem Commun (Camb). 2018 May 1;54(36):4581-4584. doi: 10.1039/c8cc02097c.

PMID:
29667658
21.

Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer.

Yao N, Jan YJ, Cheng S, Chen JF, Chung LW, Tseng HR, Posadas EM.

Am J Clin Exp Urol. 2018 Apr 1;6(2):43-54. eCollection 2018. Review.

22.

Dr. Coffey's visionary contributions to urological research in China and Japan.

Shimazaki J, Chung LW, Zhau HE, Ichikawa T.

Am J Clin Exp Urol. 2018 Apr 1;6(2):15-22. eCollection 2018. No abstract available.

23.

Design and Application of Hybrid Phosphorus Ligands for Enantioselective Rh-Catalyzed Anti-Markovnikov Hydroformylation of Unfunctionalized 1,1-Disubstituted Alkenes.

You C, Li S, Li X, Lan J, Yang Y, Chung LW, Lv H, Zhang X.

J Am Chem Soc. 2018 Apr 18;140(15):4977-4981. doi: 10.1021/jacs.8b00275. Epub 2018 Apr 4.

PMID:
29601724
24.

Brønsted-Acid-Promoted Rh-Catalyzed Asymmetric Hydrogenation of N-Unprotected Indoles: A Cocatalysis of Transition Metal and Anion Binding.

Wen J, Fan X, Tan R, Chien HC, Zhou Q, Chung LW, Zhang X.

Org Lett. 2018 Apr 20;20(8):2143-2147. doi: 10.1021/acs.orglett.8b00312. Epub 2018 Mar 30. Erratum in: Org Lett. 2018 Jul 20;20(14):4390.

PMID:
29600702
25.

Development of a novel secondary phosphine oxide-ruthenium(ii) catalyst and its application for carbonyl reduction.

Tan X, Zeng W, Zhang X, Chung LW, Zhang X.

Chem Commun (Camb). 2018 Jan 11;54(5):535-538. doi: 10.1039/c7cc07647a. Erratum in: Chem Commun (Camb). 2018 May 9;:.

PMID:
29271428
26.

Nickel-catalyzed asymmetric hydrogenation of β-acylamino nitroolefins: an efficient approach to chiral amines.

Gao W, Lv H, Zhang T, Yang Y, Chung LW, Wu YD, Zhang X.

Chem Sci. 2017 Sep 1;8(9):6419-false. doi: 10.1039/c7sc02669b. Epub 2017 Jul 4.

27.

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Tripathi M, Nandana S, Billet S, Cavassani KA, Mishra R, Chung LWK, Posadas EM, Bhowmick NA.

Oncotarget. 2017 Sep 23;8(50):87891-87902. doi: 10.18632/oncotarget.21248. eCollection 2017 Oct 20.

28.

Computational Prediction of Excited-State Carbon Tunneling in the Two Steps of Triplet Zimmerman Di-π-Methane Rearrangement.

Li X, Liao T, Chung LW.

J Am Chem Soc. 2017 Nov 22;139(46):16438-16441. doi: 10.1021/jacs.7b07539. Epub 2017 Nov 9.

PMID:
29037035
29.

Efficient syntheses of (-)-crinine and (-)-aspidospermidine, and the formal synthesis of (-)-minfiensine by enantioselective intramolecular dearomative cyclization.

Du K, Yang H, Guo P, Feng L, Xu G, Zhou Q, Chung LW, Tang W.

Chem Sci. 2017 Sep 1;8(9):6247-6256. doi: 10.1039/c7sc01859b. Epub 2017 Jul 3.

30.

Enantioselective palladium-catalyzed diboration of 1,1-disubstituted allenes.

Liu J, Nie M, Zhou Q, Gao S, Jiang W, Chung LW, Tang W, Ding K.

Chem Sci. 2017 Jul 1;8(7):5161-5165. doi: 10.1039/c7sc01254c. Epub 2017 May 16.

31.

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.

Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y.

Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30720-0. doi: 10.1016/j.eururo.2017.08.027. [Epub ahead of print]

PMID:
28927585
32.

Reactive oxygen species-mediated switching expression of MMP-3 in stromal fibroblasts and cancer cells during prostate cancer progression.

Hsieh CL, Liu CM, Chen HA, Yang ST, Shigemura K, Kitagawa K, Yamamichi F, Fujisawa M, Liu YR, Lee WH, Chen KC, Shen CN, Lin CC, Chung LWK, Sung SY.

Sci Rep. 2017 Aug 22;7(1):9065. doi: 10.1038/s41598-017-08835-9.

33.

Practical and Asymmetric Reductive Coupling of Isoquinolines Templated by Chiral Diborons.

Chen D, Xu G, Zhou Q, Chung LW, Tang W.

J Am Chem Soc. 2017 Jul 26;139(29):9767-9770. doi: 10.1021/jacs.7b04256. Epub 2017 Jul 14.

PMID:
28700227
34.

Erratum: Organocatalytic atroposelective synthesis of axially chiral styrenes.

Zheng SC, Wu S, Zhou Q, Chung LW, Ye L, Tan B.

Nat Commun. 2017 Jun 27;8:16119. doi: 10.1038/ncomms16119.

35.

Ferrocenyl chiral bisphosphorus ligands for highly enantioselective asymmetric hydrogenation via noncovalent ion pair interaction.

Chen C, Wang H, Zhang Z, Jin S, Wen S, Ji J, Chung LW, Dong XQ, Zhang X.

Chem Sci. 2016 Nov 1;7(11):6669-6673. doi: 10.1039/c6sc01845a. Epub 2016 Jun 30.

36.

Reaction Mechanism of Cu(I)-Mediated Reductive CO2 Coupling for the Selective Formation of Oxalate: Cooperative CO2 Reduction To Give Mixed-Valence Cu2(CO2•-) and Nucleophilic-Like Attack.

Lan J, Liao T, Zhang T, Chung LW.

Inorg Chem. 2017 Jun 19;56(12):6809-6819. doi: 10.1021/acs.inorgchem.6b03080. Epub 2017 May 30.

PMID:
28558249
37.

Enzyme-Inspired Chiral Secondary-Phosphine-Oxide Ligand with Dual Noncovalent Interactions for Asymmetric Hydrogenation.

Chen C, Zhang Z, Jin S, Fan X, Geng M, Zhou Y, Wen S, Wang X, Chung LW, Dong XQ, Zhang X.

Angew Chem Int Ed Engl. 2017 Jun 6;56(24):6808-6812. doi: 10.1002/anie.201701394. Epub 2017 May 11.

PMID:
28493501
38.

Organocatalytic atroposelective synthesis of axially chiral styrenes.

Zheng SC, Wu S, Zhou Q, Chung LW, Ye L, Tan B.

Nat Commun. 2017 May 3;8:15238. doi: 10.1038/ncomms15238. Erratum in: Nat Commun. 2017 Jun 27;8:16119.

39.

Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.

Endocrinology. 2017 Jul 1;158(7):2255-2268. doi: 10.1210/en.2016-1939.

40.

Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer.

Stewart PA, Khamis ZI, Zhau HE, Duan P, Li Q, Chung LWK, Sang QA.

Oncotarget. 2017 Jun 13;8(24):39209-39217. doi: 10.18632/oncotarget.16835.

41.

MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.

Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, Liu C, Wang F, Lewis M, Wang Y, Lin TP, Pan CC, Posadas EM, Zhau HE, Chung LWK.

Cancer Cell. 2017 Mar 13;31(3):368-382. doi: 10.1016/j.ccell.2017.02.003.

42.

Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, Chung LW.

Cancer Res. 2017 Mar 15;77(6):1331-1344. doi: 10.1158/0008-5472.CAN-16-0497. Epub 2017 Jan 20.

43.

Iridium-Catalyzed Asymmetric Hydrogenation of Ketones with Accessible and Modular Ferrocene-Based Amino-phosphine Acid (f-Ampha) Ligands.

Yu J, Long J, Yang Y, Wu W, Xue P, Chung LW, Dong XQ, Zhang X.

Org Lett. 2017 Feb 3;19(3):690-693. doi: 10.1021/acs.orglett.6b03862. Epub 2017 Jan 17.

PMID:
28093919
44.

Correction: Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients.

Grindel B, Li Q, Arnold R, Petros J, Zayzafoon M, Muldoon M, Stave J, Chung LW, Farach-Carson MC.

Oncotarget. 2016 Sep 13;7(37):60775. doi: 10.18632/oncotarget.11976. No abstract available.

45.

Guest-Induced Folding and Self-Assembly of Conformationally Adaptive Macrocycles into Nanosheets and Nanotubes.

Yang LP, Jia F, Zhou QH, Pan F, Sun JN, Rissanen K, Chung LW, Jiang W.

Chemistry. 2017 Jan 31;23(7):1516-1520. doi: 10.1002/chem.201605701. Epub 2017 Jan 11.

PMID:
28000968
46.

Alternative Mechanistic Strategy for Enzyme Catalysis in a Ni-Dependent Lactate Racemase (LarA): Intermediate Destabilization by the Cofactor.

Zhang X, Chung LW.

Chemistry. 2017 Mar 13;23(15):3623-3630. doi: 10.1002/chem.201604893. Epub 2016 Dec 16.

PMID:
27883243
47.

Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.

Li Q, Yin L, Jones LW, Chu GC, Wu JB, Huang JM, Li Q, You S, Kim J, Lu YT, Mrdenovic S, Wang R, Freeman MR, Garraway I, Lewis MS, Chung LW, Zhau HE.

Oncotarget. 2016 Dec 20;7(51):84645-84657. doi: 10.18632/oncotarget.13175.

48.

Applications of circulating tumor cells for prostate cancer.

Cheng S, Chen JF, Lu YT, Chung LWK, Tseng HR, Posadas EM.

Asian J Urol. 2016 Oct;3(4):254-259. doi: 10.1016/j.ajur.2016.09.004. Epub 2016 Sep 14. Review.

49.

Cultured circulating tumor cells and their derived xenografts for personalized oncology.

Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK.

Asian J Urol. 2016 Oct;3(4):240-253. doi: 10.1016/j.ajur.2016.08.005. Epub 2016 Aug 25. Review.

50.

Biology and therapy of urological cancer metastasis.

Posadas EM, McConkey DJ, Chung LWK.

Asian J Urol. 2016 Oct;3(4):167-169. doi: 10.1016/j.ajur.2016.09.008. Epub 2016 Sep 23. No abstract available.

Supplemental Content

Loading ...
Support Center